Clinical Epidemiology and Ageing

Safety and efficacy of immunotherapy according to the age threshold of 80 years.

Mebarki S, Pamoukdjian F, Pierro M, Poisson J, Baldini C, Taieb J, Fabre E, Canoui-Poitrine F, Oudard S, Paillaud E Bull Cancer. 2023;110(5):570-580.

BACKGROUND: To compare safety and efficacy of ICIs among patients<80 and those ≥80 years of age.

METHODS: A single-center retrospective observational cohort study comparing patients<80 and ≥80 years of age matched for cancer site (lung vs others) and participation in a clinical trial.

PRIMARY ENDPOINT: grade ≥2 toxicity during the first three months of ICI therapy. The two groups were compared using univariate and multivariate regression.

RESULTS: Two hundred and ten consecutive patients were recruited, with the following characteristics: mean age: 66.5±16.8, 20% aged ≥80 years, 75% male, 97% ECOG-PS ≤ 2, 78% G8-index ≤ 14/17, 80% lung or kidney cancer, and 97% metastatic cancer. The grade ≥2 toxicity rate during the first three months of ICI therapy was 68%. Patients aged ≥80 years of age had a more significant (P<0.05) proportion of grade ≥2 non-hematological toxicities (64% vs 45%) than those aged<80 years: rash (14% vs 4%), arthralgia (7.1% vs 0.6%), colitis (4.7% vs 0.6%), cytolysis (7.1% vs 1.2%), gastrointestinal bleeding (2.4% vs 0%), onycholysis (2.4% vs 0%), oral mucositis (2.4% vs 0%), psoriasis (2.4% vs 0%), or other skin toxicities (25% vs 3%). Efficacy among patients ≥80 and<80 years of age was comparable.

CONCLUSIONS: Although non-hematological toxicities affected 20% more patients aged ≥80 years, hematological toxicities and efficacy were comparable between patients aged ≥80 and<80 years with advanced cancer and treated with ICIs.

MeSH terms: Aged; Aged, 80 and over; Carcinoma, Renal Cell; Female; Humans; Immunotherapy; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Observational Studies as Topic; Retrospective Studies
DOI: 10.1016/j.bulcan.2023.02.010